NASDAQ:ASMB

Assembly Biosciences Stock Forecast, Price & News

$3.47

0.00 (0.00 %)

(As of 07/30/2021 12:00 AM ET)

Add

Compare

Today's Range

$3.36

▼

$3.48

50-Day Range

$3.39

▼

$4.46

52-Week Range

$3.32

▼

$23.39

Volume814,433 shs

Average Volume1.19 million shs

Market Capitalization$139.35 million

P/E RatioN/A

Dividend YieldN/A

Beta0.33

30 days | 90 days | 365 days | Advanced Chart

Receive ASMB News and Ratings via Email

Sign-up to receive the latest news and ratings for Assembly Biosciences and its competitors with MarketBeat's FREE daily newsletter.

About Assembly Biosciences

Assembly Biosciences, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection. Its product candidates include Vebicorvir to treat patients with chronic HBV infection; ABI-H2158, which is in Phase II clinical study for chronic HBV infection; ABI-H3733 that has completed Phase Ia clinical study for the treatment of HBV. The company has collaboration agreements with Allergan Pharmaceuticals International Limited; BeiGene, Ltd.; and Arbutus Biopharma Corporation, as well as strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was founded in 2005 and is headquartered in South San Francisco, California.

Analysts Estimate Assembly Biosciences (ASMB) to Report a Decline in Earnings: What to Look Out for
July 28, 2021 | finance.yahoo.com

Assembly Biosciences, Inc. (NASDAQ:ASMB) Receives Average Rating of "Buy" from Analysts
July 28, 2021 | americanbankingnews.com

Somerville Street Sweeper Bursts Into Flames Near Assembly Row
July 26, 2021 | msn.com

Fuel Prices, Police Bill: A Likely 'Stormy' Monsoon Session of Bihar Assembly Set to Begin on Monday
July 25, 2021 | msn.com

Newsom Signs Assembly Bill Targeting Organized Retail Theft Rings
July 21, 2021 | msn.com

GM Flint Assembly cuts production due to semiconductor shortage
July 21, 2021 | msn.com

Anannyah Kumari, First Transgender to File Nomination in Kerala Assembly Elections, Found Dead
July 21, 2021 | msn.com

BTS to attend the UN General Assembly again, appointed as Special Presidential Envoy for Culture
July 21, 2021 | msn.com

Analysts Anticipate Assembly Biosciences, Inc. (NASDAQ:ASMB) Will Announce Quarterly Sales of $3.25 Million
July 21, 2021 | americanbankingnews.com

Outsourced Semiconductor Assembly and Test Services (OSAT) Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021-2026)
July 20, 2021 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:ASMB
Previous Symbol
CUSIP92282210
CIK1426800
Webwww.assemblybio.com
Phone833-509-4583
Employees139
Year FoundedN/A

Sales & Book Value

Annual Sales$79.11 million
Price / Sales1.76
Cash FlowN/A
Price / Cash FlowN/A
Book Value$7.29 per share
Price / Book0.48

Profitability

EPS (Most Recent Fiscal Year)($1.75)
Net Income$-62,150,000.00
Net Margins-78.57%
Return on Equity-24.46%
Return on Assets-21.56%

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares40,158,000
Market Cap$139.35 million
Next Earnings Date8/4/2021 (Estimated)
OptionableOptionable

MarketRank^™

Overall MarketRank^™

1.76 out of 5 stars

Medical Sector

598th out of 2,216 stocks

Pharmaceutical Preparations Industry

304th out of 869 stocks

3.3 Analyst's Opinion

Consensus Rating
Assembly Biosciences has received a consensus rating of Buy. The company's average rating score is 2.60, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $11.25, Assembly Biosciences has a forecasted upside of 224.2% from its current price of $3.47.
Amount of Analyst Coverage
Assembly Biosciences has only been the subject of 2 research reports in the past 90 days.

3.2 Community Rank

Outperform Votes
Assembly Biosciences has received 234 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Assembly Biosciences has received 136 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Assembly Biosciences has received 63.24% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Assembly Biosciences and other stocks. Vote “Outperform” if you believe ASMB will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ASMB will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Assembly Biosciences does not currently pay a dividend.
Dividend Growth
Assembly Biosciences does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Assembly Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $16,640.00 in company stock.
Percentage Held by Insiders
Only 3.90% of the stock of Assembly Biosciences is held by insiders.
Percentage Held by Institutions
71.60% of the stock of Assembly Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Assembly Biosciences are expected to decrease in the coming year, from ($2.60) to ($2.76) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Assembly Biosciences is -2.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Assembly Biosciences is -2.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Assembly Biosciences has a P/B Ratio of 0.48. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Assembly Biosciences (NASDAQ:ASMB) Frequently Asked Questions

Is Assembly Biosciences a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Assembly Biosciences in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Assembly Biosciences stock.
View analyst ratings for Assembly Biosciences or view top-rated stocks.

What stocks does MarketBeat like better than Assembly Biosciences?

Wall Street analysts have given Assembly Biosciences a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Assembly Biosciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Assembly Biosciences?

Assembly Biosciences saw a decrease in short interest during the month of July. As of July 15th, there was short interest totaling 4,200,000 shares, a decrease of 12.1% from the June 30th total of 4,780,000 shares. Based on an average trading volume of 1,190,000 shares, the days-to-cover ratio is presently 3.5 days. Currently, 11.5% of the shares of the company are sold short.
View Assembly Biosciences' Short Interest.

When is Assembly Biosciences' next earnings date?

Assembly Biosciences is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Assembly Biosciences.

How were Assembly Biosciences' earnings last quarter?

Assembly Biosciences, Inc. (NASDAQ:ASMB) posted its quarterly earnings results on Wednesday, May, 5th. The biopharmaceutical company reported ($0.69) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.79) by $0.10. Assembly Biosciences had a negative trailing twelve-month return on equity of 24.46% and a negative net margin of 78.57%.
View Assembly Biosciences' earnings history.

How has Assembly Biosciences' stock price been impacted by COVID-19?

Assembly Biosciences' stock was trading at $15.60 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ASMB stock has decreased by 77.8% and is now trading at $3.47.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for ASMB?

5 Wall Street analysts have issued 12-month price targets for Assembly Biosciences' shares. Their forecasts range from $7.00 to $15.00. On average, they expect Assembly Biosciences' share price to reach $11.25 in the next twelve months. This suggests a possible upside of 224.2% from the stock's current price.
View analysts' price targets for Assembly Biosciences or view top-rated stocks among Wall Street analysts.

Who are Assembly Biosciences' key executives?

Assembly Biosciences' management team includes the following people:

Dr. John G. McHutchison A.O., M.D., FRACP, CEO, Pres & Director (Age 63, Pay $1.44M)
Dr. William E. Delaney IV, Ph.D., Chief Scientific Officer (Age 49, Pay $450.87k)
Mr. Jason A. Okazaki, Chief Legal & Bus. Officer and Corp. Sec. (Age 45, Pay $703.27k)
Dr. Uri A. Lopatin, Co-Founder and Clinical & Scientific Advisor (Age 49)
Dr. Adam Zlotnick, Co-Founder, Chief Scientific Advisor and Chair of Hbv & Virology Science Advisory Board
Mr. Michael P. Samar, Sr. VP of Fin. & Bus. Operations and Principal Financial & Accounting Officer (Age 49)
Ms. Lauren Glaser, Sr. VP of Investor Relations & Corp. Affairs
Ms. Jennifer A. Troia MHROD, SPHR, SHRM-SCP, Sr. VP of HR and Organization Devel.
Dr. Richard J. Colonno, Sr. Advisor (Age 71)
Dr. Tharaknath Rao, Head of Microbiome Clinical Devel. & Sr. VP

What is John McHutchison's approval rating as Assembly Biosciences' CEO?

5 employees have rated Assembly Biosciences CEO John McHutchison on Glassdoor.com. John McHutchison has an approval rating of 80% among Assembly Biosciences' employees.

Who are some of Assembly Biosciences' key competitors?

Some companies that are related to Assembly Biosciences include Johnson & Johnson (JNJ), Pfizer (PFE), Eli Lilly and (LLY), AbbVie (ABBV), Merck & Co., Inc. (MRK), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics Public (HZNP), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Nektar Therapeutics (NKTR), Pacira BioSciences (PCRX), Corcept Therapeutics (CORT) and Supernus Pharmaceuticals (SUPN).
View all of ASMB's competitors.

What other stocks do shareholders of Assembly Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Assembly Biosciences investors own include BioDelivery Sciences International (BDSI), Exelixis (EXEL), TG Therapeutics (TGTX), Arbutus Biopharma (ABUS), AVEO Pharmaceuticals (AVEO), Sorrento Therapeutics (SRNE), AbbVie (ABBV), BioCryst Pharmaceuticals (BCRX), Gilead Sciences (GILD) and Blueprint Medicines (BPMC).

What is Assembly Biosciences' stock symbol?

Assembly Biosciences trades on the NASDAQ under the ticker symbol "ASMB."

Who are Assembly Biosciences' major shareholders?

Assembly Biosciences' stock is owned by a variety of institutional and retail investors. Top institutional investors include Marquette Asset Management LLC (0.06%). Company insiders that own Assembly Biosciences stock include Jacqueline Sybil Papkoff, Luisa M Stamm, Richard James Colonno, Timothy A Springer and William E Iv Delaney.
View institutional ownership trends for Assembly Biosciences.

Which institutional investors are buying Assembly Biosciences stock?

ASMB stock was purchased by a variety of institutional investors in the last quarter, including Marquette Asset Management LLC.
View insider buying and selling activity for Assembly Biosciences or or view top insider-buying stocks.

How do I buy shares of Assembly Biosciences?

Shares of ASMB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Assembly Biosciences' stock price today?

One share of ASMB stock can currently be purchased for approximately $3.47.

How much money does Assembly Biosciences make?

Assembly Biosciences has a market capitalization of $139.35 million and generates $79.11 million in revenue each year. The biopharmaceutical company earns $-62,150,000.00 in net income (profit) each year or ($1.75) on an earnings per share basis.

How many employees does Assembly Biosciences have?

Assembly Biosciences employs 139 workers across the globe.

What is Assembly Biosciences' official website?

The official website for Assembly Biosciences is www.assemblybio.com.

Where are Assembly Biosciences' headquarters?

Assembly Biosciences is headquartered at 331 OYSTER POINT BOULEVARD FOURTH FLOOR, SOUTH SAN FRANCISCO CA, 94080.

How can I contact Assembly Biosciences?

Assembly Biosciences' mailing address is 331 OYSTER POINT BOULEVARD FOURTH FLOOR, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 833-509-4583 or via email at [email protected]

This page was last updated on 7/30/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here